Catalent announced the completion of a $30 million project at its facility in Limoges, France, focused on biopharmaceutical development and manufacturing of pharmaceutical products.
Catalent announced on March 16, 2022 that a $30 million (€27 million) project at its factory in Limoges, France has been completed. The project focused on biopharmaceutical development, pharmaceutical filling/finishing services and packaging.
The project modernized the Limoges site to support large molecule programs and increase the capacity to develop small molecule injectable dosage forms. The expansion includes the installation of a new flexible small to medium scale filling line capable of handling vials, syringes or cartridges under barrier isolator technology. Improvements to analytical and quality control laboratories have also been included, which supports clinical packaging, cold storage and regulatory capabilities.
The Limoges site will expand Catalent Biologics’ global network with integrated early-stage clinical development and small-scale commercial manufacturing, which can gradually transition to later-stage and larger-scale commercial supply from its other facilities in Europe and North America. The site is also expected to create up to 80 additional jobs through the expansion.
“This investment has transformed the Limoges site into a world-class facility to support the development of early-stage, small-scale commercial biologics, and provides customers with integrated services to accelerate programs to and through the clinic, and finally on the market,” commented Mike Riley, president of Catalent, Biotherapeutics, in the press release. “Even before completion, several clinical and commercial customers have already signed contracts for programs to be undertaken at the site. Limoges will now work closely with other Catalent facilities in Europe and the United States to provide globally integrated solutions for a range of therapies.